173 related articles for article (PubMed ID: 19958049)
1. Combined environmental risk assessment for 5-fluorouracil and capecitabine in Europe.
Straub JO
Integr Environ Assess Manag; 2010 Jul; 6 Suppl():540-66. PubMed ID: 19958049
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of measured and predicted environmental concentrations of selected human pharmaceuticals and personal care products.
Liebig M; Moltmann JF; Knacker T
Environ Sci Pollut Res Int; 2006 Mar; 13(2):110-9. PubMed ID: 16612900
[TBL] [Abstract][Full Text] [Related]
3. An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions.
Straub JO
Ecotoxicol Environ Saf; 2009 Sep; 72(6):1625-34. PubMed ID: 19560203
[TBL] [Abstract][Full Text] [Related]
4. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
Straub JO
Toxicol Lett; 2002 Oct; 135(3):231-7. PubMed ID: 12270681
[TBL] [Abstract][Full Text] [Related]
5. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
Straub JO
Toxicol Lett; 2002 May; 131(1-2):137-43. PubMed ID: 11988366
[TBL] [Abstract][Full Text] [Related]
6. Environmental assessment of Norwegian priority pharmaceuticals based on the EMEA guideline.
Grung M; Källqvist T; Sakshaug S; Skurtveit S; Thomas KV
Ecotoxicol Environ Saf; 2008 Oct; 71(2):328-40. PubMed ID: 18068226
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1.
Weltman R; Brands CM; Corral E; Desmares-Koopmans MJ; Migchielsen MH; Oudhoff KA; de Roode DF
Chemosphere; 2012 Jun; 87(11):1323-9. PubMed ID: 22365278
[TBL] [Abstract][Full Text] [Related]
8. Environmental risk assessment of medicinal products for human use according to European Commission recommendations.
Huschek G; Hansen PD; Maurer HH; Krengel D; Kayser A;
Environ Toxicol; 2004 Jun; 19(3):226-40. PubMed ID: 15101038
[TBL] [Abstract][Full Text] [Related]
9. Deterministic and probabilistic acute-based environmental risk assessment for naproxen for western Europe.
Straub JO; Stewart KM
Environ Toxicol Chem; 2007 Apr; 26(4):795-806. PubMed ID: 17447566
[TBL] [Abstract][Full Text] [Related]
10. Environmental risk assessment of hydrotropes in the United States, Europe, and Australia.
Stanton K; Tibazarwa C; Certa H; Greggs W; Hillebold D; Jovanovich L; Woltering D; Sedlak R
Integr Environ Assess Manag; 2010 Jan; 6(1):155-63. PubMed ID: 19558203
[TBL] [Abstract][Full Text] [Related]
11. Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: Case study using the European risk assessment framework.
Oakes KD; Coors A; Escher BI; Fenner K; Garric J; Gust M; Knacker T; Küster A; Kussatz C; Metcalfe CD; Monteiro S; Moon TW; Mennigen JA; Parrott J; Péry AR; Ramil M; Roennefahrt I; Tarazona JV; Sánchez-Argüello P; Ternes TA; Trudeau VL; Boucard T; Van Der Kraak GJ; Servos MR
Integr Environ Assess Manag; 2010 Jul; 6 Suppl():524-39. PubMed ID: 20821717
[TBL] [Abstract][Full Text] [Related]
12. Environmental risk assessment of antibiotics: an intensive care unit analysis.
de Souza SM; Vasconcelos EC; Dziedzic M; de Oliveira CM
Chemosphere; 2009 Nov; 77(7):962-7. PubMed ID: 19744697
[TBL] [Abstract][Full Text] [Related]
13. Environmental Risk Assessment for the Active Pharmaceutical Ingredient Mycophenolic Acid in European Surface Waters.
Straub JO; Oldenkamp R; Pfister T; Häner A
Environ Toxicol Chem; 2019 Oct; 38(10):2259-2278. PubMed ID: 31225916
[TBL] [Abstract][Full Text] [Related]
14. Predicting concentrations of the cytostatic drugs cyclophosphamide, carboplatin, 5-fluorouracil, and capecitabine throughout the sewage effluents and surface waters of Europe.
Johnson AC; Oldenkamp R; Dumont E; Sumpter JP
Environ Toxicol Chem; 2013 Sep; 32(9):1954-61. PubMed ID: 23893496
[TBL] [Abstract][Full Text] [Related]
15. Environmental risk assessment of ivermectin: A case study.
Liebig M; Fernandez AA; Blübaum-Gronau E; Boxall A; Brinke M; Carbonell G; Egeler P; Fenner K; Fernandez C; Fink G; Garric J; Halling-Sørensen B; Knacker T; Krogh KA; Küster A; Löffler D; Cots MA; Pope L; Prasse C; Römbke J; Rönnefahrt I; Schneider MK; Schweitzer N; Tarazona JV; Ternes TA; Traunspurger W; Wehrhan A; Duis K
Integr Environ Assess Manag; 2010 Jul; 6 Suppl():567-87. PubMed ID: 20821718
[TBL] [Abstract][Full Text] [Related]
16. Fluorouracil in the environment: analysis, occurrence, degradation and transformation.
Kosjek T; Perko S; Žigon D; Heath E
J Chromatogr A; 2013 May; 1290():62-72. PubMed ID: 23578484
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the environmental fate and effects of the PPARgamma receptor agonist, pioglitazone.
Weltman R; Hargreaves T; Knight B; Wardrope L
Chemosphere; 2011 Apr; 83(4):391-9. PubMed ID: 21316075
[TBL] [Abstract][Full Text] [Related]
18. Environmental risk assessment of human pharmaceuticals in the European Union: A case study with the β-blocker atenolol.
Küster A; Alder AC; Escher BI; Duis K; Fenner K; Garric J; Hutchinson TH; Lapen DR; Péry A; Römbke J; Snape J; Ternes T; Topp E; Wehrhan A; Knacker T
Integr Environ Assess Manag; 2010 Jul; 6 Suppl():514-23. PubMed ID: 19886730
[TBL] [Abstract][Full Text] [Related]
19. An Environmental Risk Assessment for Human-Use Trimethoprim in European Surface Waters.
Straub JO
Antibiotics (Basel); 2013 Mar; 2(1):115-62. PubMed ID: 27029296
[TBL] [Abstract][Full Text] [Related]
20. Experiences with the OECD 308 transformation test: a human pharmaceutical perspective.
Ericson JF; Smith RM; Roberts G; Hannah B; Hoeger B; Ryan J
Integr Environ Assess Manag; 2014 Jan; 10(1):114-24. PubMed ID: 23794155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
